AVBP

$24.25-0.06 (-0.25%)

Market OpenAs of Mar 17, 7:00 PM UTC

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$24.25
Potential Upside
5%
Whystock Fair Value$25.46
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is fir...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
1.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-58.88%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
12.06

Recent News

Zacks
Mar 10, 2026

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 70.4% in ArriVent BioPharma, Inc. (AVBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 10, 2026

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?

Here is how ArriVent BioPharma, Inc. (AVBP) and Ocugen (OCGN) have performed compared to their sector so far this year.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
24/7 Wall St.
Dec 23, 2025

Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More

Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event just 48 hours away, you can bet the trading volume will fall off a cliff. Wednesday will be a day for the junior ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Nov 12, 2025

We Think ArriVent BioPharma (NASDAQ:AVBP) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Jul 21, 2025

New Strong Sell Stocks for July 21st

CDZI, AVBP and ACCO have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2025.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.